Official websites use. Share sensitive information only on official, secure websites. This article was submitted to Pituitary Endocrinology, a section of the journal Frontiers in Endocrinology. The use, distribution or reproduction in other forums is permitted, provided the original author s and the copyright owner s are credited and that the original publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these terms. Purpose: Non-compliance to recombinant human growth hormone r-hGH therapy in adult growth hormone deficiency aGHD is a major concern for endocrinologist, as it affects significantly efficacy outcomes. This month observational study was aimed to assess adherence in GHD patients treated with r-hGH administered via Easypod TM , an electronic, fully automated injection device designed to track the time, date and dose administered.
Methods: 65 patients receiving r-hGH therapy were included in the study and 32 completed the study. The primary endpoint, adherence to treatment, was calculated as the proportion of injections correctly administered during the observational period out of the expected total number of injections.
As secondary end-point, serum IGF-1 levels were also determined. Females are more compliant than males. Adherence levels are correlated to IGF-1 ones. Conclusions: Adherence is connected with therapy efficacy in aGHD.
The injection-recording system and other characteristics of Easypod TM could enhance the ability of physicians to monitor adherence to r-hGH treatment, identifying non-compliant patients, thus enabling physicians to modify their management to maximize the benefits of the treatment. Adult growth hormone deficiency aGHD is a disorder characterized by a reduction in GH secretion caused by congenital or acquired diseases affecting the hypothalamus or pituitary gland 1.
